Search CommunityWalk:


Sequella, Inc.

9610 Medical Center Drive, Suite 200
Rockville, MD 20850, USA

Category: Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Sequella Inc. is a biopharmaceutical company focused on commercializing improved treatments for serious infectious diseases. It was founded in 1997 by Carol A. Nacy and Leo Einck with a mission to develop and commercialize new, more effective therapeutics for serious or life-threatening infectious diseases.

Sequella develops novel small molecule and natural product-based therapeutics for infectious diseases, starting with TB. Its initial research programs identify new scaffolds with antibacterial and antifungal activity and several compound libraries were prepared using focused combinatorial chemistry and modern synthetic techniques. It has developed and validated several high-throughput screening assays that are used to analyze the libraries for target pathogen activity and identify the most promising compounds for clinical development. Its drug candidates have broad market potential with applications in Tuberculosis, Peptic Ulcer Disease and Gastric Cancer, Fungal Diseases, Crohn's Disease, Bacterial Pneumonia, and a number of other infectious diseases.

Sequella's pipeline includes: SQ109, SQ609 and SQ641 for the treatment of TB; SQ109 - for the treatment of tuberculosis, duodenal ulcers, gastric carcinoma and Candida glabrata infection.

Sequella has partnerships with The University of Maryland, Baltimore (UMB), PATH (Program for Appropriate Technology in Health), Chembio Diagnostic Systems, Inc., BioFactura, Inc., Tibotec Pharmaceuticals Limited, Johnson & Johnson, National Institutes of Health, Daiichi Sankyo Company, Limited, Sankyo Co., Ltd. etc.